Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field.
[inlinead]
September 10 - 12, 2024
Düsseldorf, Germany
September 10 - 12, 2024
Falls Church, VA
Insights from the world’s foremost thought leaders delivered to your inbox.
2022-10-18
02:00 PM - 03:00 PM BST
2022-06-01
04:30 PM - 05:30 PM CET
2022-04-28
01:00 PM - 02:00 PM EST
Reach Pharmaceuticals & Biotechnology professionals through cost-effective marketing opportunities to deliver your message, position yourself as a thought leader, and introduce new products, techniques and strategies to the market.
Join Pharma & Biotech today and interact with a vibrant network of professionals, keeping up to date with the industry by accessing our wealth of articles, videos, live conferences and more.
Pharma IQ, a division of IQPC
Become a Member today!
Already an IQPC Community Member?
Sign in Here or Forgot Password
Sign up now and get FREE access to our extensive library of reports, infographics, whitepapers, webinars and online events from the world’s foremost thought leaders.
We respect your privacy, by clicking 'Subscribe' you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object. For further information on how we process and monitor your personal data click here. You can unsubscribe at any time.
